Led by Teri Schreiner, an associate professor of pediatrics-neurology at the University of Colorado School of Medicine, the observed PK/PD profile of ocrelizumab in this pediatric population was similar to that seen in adults. In addition, no new T1-gadolinium-enhancing lesions were reported at week 12.
CU Anschutz
Administrative Pavilion
13123 E. 16th Ave.
B065
Aurora, CO 80045